Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Lyell Immunopharma, Inc. (LYEL) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/15/2023 144 Form 144 - Report of proposed sale of securities:
08/15/2023 144 Form 144 - Report of proposed sale of securities:
08/15/2023 144 Form 144 - Report of proposed sale of securities:
08/15/2023 144 Form 144 - Report of proposed sale of securities:
08/08/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/08/2023 8-K Quarterly results
Docs: "Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2023"
07/17/2023 144 Form 144 - Report of proposed sale of securities:
07/17/2023 144 Form 144 - Report of proposed sale of securities:
07/17/2023 144 Form 144 - Report of proposed sale of securities:
07/17/2023 144 Form 144 - Report of proposed sale of securities:
06/06/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
05/04/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/04/2023 8-K Quarterly results
04/27/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/27/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
02/28/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2022"
02/13/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/09/2023 SC 13G VANGUARD GROUP INC reports a 5% stake in Lyell Immunopharma Inc.
12/16/2022 8-K Quarterly results
11/08/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/08/2022 8-K Quarterly results
10/24/2022 8-K Quarterly results
10/06/2022 8-K Quarterly results
08/04/2022 S-3ASR Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers:
08/04/2022 10-Q Quarterly Report for the period ended June 30, 2022
08/04/2022 8-K Quarterly results
Docs: "Lyell Immunopharma Reports Second Quarter Financial Results and Business Highlights"
06/13/2022 8-K Quarterly results
05/10/2022 10-Q Quarterly Report for the period ended March 31, 2022
05/10/2022 8-K Quarterly results
04/28/2022 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/29/2022 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
03/29/2022 10-K Annual Report for the period ended December 31, 2021
03/29/2022 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Lyell Immunopharma Reports Fourth Quarter and Full Year 2021 Financial Results and Business Highlights"
02/15/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy